Charles Schwab’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-285,058
| Closed | -$10.7M | – | 3631 |
|
|
2021
Q1 | $10.7M | Sell |
285,058
-30,417
| -10% | -$758K | ﹤0.01% | 1922 |
|
|
2020
Q4 | $5.37M | Buy |
315,475
+31,716
| +11% | +$397K | ﹤0.01% | 2184 |
|
|
2020
Q3 | $1.33M | Buy |
283,759
+70,133
| +33% | +$356K | ﹤0.01% | 2614 |
|
|
2020
Q2 | $1.3M | Sell |
213,626
-1,289
| -0.6% | -$5.31K | ﹤0.01% | 2556 |
|
|
2020
Q1 | $488K | Buy |
214,915
+3,061
| +1% | +$13K | ﹤0.01% | 2723 |
|
|
2019
Q4 | $973K | Sell |
211,854
-5,992
| -3% | -$23.7K | ﹤0.01% | 2604 |
|
|
2019
Q3 | $845K | Buy |
217,846
+31,894
| +17% | +$175K | ﹤0.01% | 2619 |
|
|
2019
Q2 | $1.12M | Sell |
185,952
-18,015
| -9% | -$172K | ﹤0.01% | 2543 |
|
|
2019
Q1 | $2.73M | Buy |
203,967
+15,543
| +8% | +$177K | ﹤0.01% | 2253 |
|
|
2018
Q4 | $1.75M | Sell |
188,424
-2,131
| -1% | -$25.4K | ﹤0.01% | 2378 |
|
|
2018
Q3 | $2.65M | Buy |
190,555
+14,660
| +8% | +$218K | ﹤0.01% | 2342 |
|
|
2018
Q2 | $2.78M | Buy |
175,895
+22,572
| +15% | +$394K | ﹤0.01% | 2269 |
|
|
2018
Q1 | $2.63M | Buy |
153,323
+23,616
| +18% | +$461K | ﹤0.01% | 2223 |
|
|
2017
Q4 | $2.84M | Sell |
129,707
-11,044
| -8% | -$355K | ﹤0.01% | 2177 |
|
|
2017
Q3 | $5.76M | Buy |
140,751
+28,954
| +26% | +$909K | 0.01% | 1805 |
|
|
2017
Q2 | $3.37M | Sell |
111,797
-10,743
| -9% | -$335K | ﹤0.01% | 2016 |
|
|
2017
Q1 | $4.43M | Sell |
122,540
-83,016
| -40% | -$3.66M | ﹤0.01% | 1829 |
|
|
2016
Q4 | $10.3M | Sell |
205,556
-12,322
| -6% | -$647K | 0.01% | 1233 |
|
|
2016
Q3 | $11.4M | Buy |
217,878
+73,886
| +51% | +$3.53M | 0.01% | 1067 |
|
|
2016
Q2 | $5.96M | Buy |
143,992
+98,353
| +216% | +$4.28M | 0.01% | 1456 |
|
|
2016
Q1 | $1.85M | Buy |
45,639
+3,139
| +7% | +$108K | ﹤0.01% | 2089 |
|
|
2015
Q4 | $1.76M | Buy |
42,500
+9,200
| +28% | +$308K | ﹤0.01% | 2145 |
|
|
2015
Q3 | $513K | Hold |
33,300
| – | – | ﹤0.01% | 2616 |
|
|
2015
Q2 | $828K | Hold |
33,300
| – | – | ﹤0.01% | 2502 |
|
|
2015
Q1 | $761K | Buy |
33,300
+8,000
| +32% | +$202K | ﹤0.01% | 2475 |
|
|
2014
Q4 | $684K | Hold |
25,300
| – | – | ﹤0.01% | 2511 |
|
|
2014
Q3 | $297K | Hold |
25,300
| – | – | ﹤0.01% | 2803 |
|
|
2014
Q2 | $394K | Buy |
+25,300
| New | +$363K | ﹤0.01% | 2736 |
|
Charles Schwab's FPRX Position: Q2 2021 in Review
Charles Schwab sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 285,058 shares — an estimated $10.7M sold.
Charles Schwab first reported a position in FPRX in Q2 2014 and held it in 28 quarters. The position peaked at $11.4M in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Charles Schwab reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Charles Schwab sold 285,058 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $10.7M.
- Charles Schwab first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and held it in 28 quarters.
- Charles Schwab's Five Prime Therapeutics, Inc. position peaked at $11.4M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.